{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:00:07Z","timestamp":1780477207966,"version":"3.54.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to investigate the association between the mean absorbed tumor dose (ATD) and treatment response in patients who underwent transarterial radioembolization for colorectal cancer liver metastases (CRCLM). Furthermore, we sought to determine the prognostic value of mean ATD in predicting overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-center observational study was conducted in a tertiary referral hospital. A total of 56 patients who received transarterial radioembolization for CRCLM were included. Posttherapy Y-90 PET\/computed tomography images were retrospectively analyzed for dosimetric evaluation. Mean absorbed doses were calculated for the whole normal liver, perfused liver, and all tumors. Treatment response was assessed at 3 months after therapy using liver MRI according to the modified RECIST 1.0 criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-six patients (36 males, 20 females; median age, 64 years) were included in the analysis. Radioembolization was performed with glass microspheres in 30 patients (54%) and with resin microspheres in 26 patients (46%). The two groups were comparable in terms of age, sex, and prior therapies. In total, 234 lesions (83 treated with resin and 151 with glass microspheres) were included in the lesion-based dose\u2013response analysis. Overall, complete response (CR), partial response (PR), stable disease, and progressive disease (PD) were observed in 73 (31%), 119 (51%), 22 (9%), and 20 (9%) lesions, respectively. In the glass microsphere group (151 lesions), CR, PR, stable disease, and PD were observed in 63 (42%), 62 (41%), 12 (8%), and 14 (9%) lesions, respectively. Receiver operating characteristic curve analysis demonstrated a significant correlation between mean ATD and treatment response (PR\u2005+\u2005CR vs. stable disease\u2005+\u2005PD), with an AUC of 0.805 [95% confidence interval (CI): 0.714\u20130.896,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.001]. In the resin microsphere group, CR, PR, stable disease, and PD were observed in 10 (12%), 57 (69%), 10 (12%), and 6 (7%) lesions, respectively. A similar correlation between mean ATD and response was also observed in this group (AUC\u2005=\u20050.767, 95% CI: 0.611\u20130.923,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.001). During the follow-up period, 43 patients (78%) died. The mean overall survival for the entire cohort was 15.7\u2005\u00b1\u20051.8 months (95% CI: 12.0\u201319.5 months). No significant difference in overall survival was found between patients treated with glass and resin microspheres (16.3\u2005\u00b1\u20052.4 vs. 14.2\u2005\u00b1\u20052.5 months,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.7).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There is a strong correlation between ATD and tumor response in CRCLM patients treated with both resin and glass microspheres. Escalation of ATD through multicompartment dosimetry may enhance treatment efficacy without increasing the risk of hepatotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002148","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:00:15Z","timestamp":1774944015000},"page":"773-779","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Radioembolization of colorectal liver metastases: comparative dose\u2013response of resin and glass microspheres"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6199-8551","authenticated-orcid":false,"given":"Cigdem","family":"Soydal","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irem","family":"Mesci","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre Can","family":"Celebioglu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Ankara University Medical School, Ankara, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ecenur Dursun","family":"Avci","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digdem Kuru","family":"Oz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Ankara University Medical School, Ankara, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sadik","family":"Bilgic","sequence":"additional","affiliation":[{"name":"Department of Radiology, Ankara University Medical School, Ankara, Turkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriye Ozlem","family":"Kucuk","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"R1-20260603","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00270-018-1982-4","article-title":"Radioembolisation in europe: a survey amongst CIRSE members.","volume":"41","author":"Reinders","year":"2018","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R2-20260603","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00259-015-3157-8","article-title":"Clinical impact of (99m)Tc-MAA SPECT\/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.","volume":"43","author":"Garin","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R3-20260603","first-page":"1097","article-title":"Transarterial radioembolization in the TACOME trial: dosimetric analysis and clinical features in predicting response and overall survival.","volume":"66","author":"Soydal","year":"2025","journal-title":"J Nucl Med"},{"key":"R4-20260603","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40658-021-00394-3","article-title":"EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres.","volume":"8","author":"Chiesa","year":"2021","journal-title":"EJNMMI Phys"},{"key":"R5-20260603","first-page":"226","article-title":"Updated recommendations for dosing of glass microspheres (TheraSphere) in hepatocellular carcinoma.","volume":"28","author":"Salem","year":"2011","journal-title":"Semin Intervent Radiol"},{"key":"R6-20260603","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijrobp.2006.11.060","article-title":"Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium.","volume":"68","author":"Kennedy","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20260603","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1118\/1.3608909","article-title":"90Y microspheres dose verification and dosimetry. Recommendations of the American Association of Physicists in Medicine Task Group 194.","volume":"38","author":"Dezarn","year":"2011","journal-title":"Med Phys"},{"key":"R10-20260603","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","article-title":"SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.","volume":"34","author":"van Hazel","year":"2016","journal-title":"J Clin Oncol"},{"key":"R11-20260603","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:00:22Z","timestamp":1780473622000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002148","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"2025-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}